Full Text:   <635>

Summary:  <206>

Suppl. Mater.: 

CLC number: 

On-line Access: 2023-03-10

Received: 2022-08-11

Revision Accepted: 2022-11-01

Crosschecked: 2023-03-13

Cited: 0

Clicked: 727

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Li JIANG

https://orcid.org/0000-0003-4890-1206

Ji CAO

https://orcid.org/0000-0003-2813-6404

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2023 Vol.24 No.3 P.207-220

http://doi.org/10.1631/jzus.B2200405


Disulfiram enhances the antitumor activity of cisplatin by inhibiting the Fanconi anemia repair pathway


Author(s):  Meng YUAN, Qian WU, Mingyang ZHANG, Minshan LAI, Wenbo CHEN, Jianfeng YANG, Li JIANG, Ji CAO

Affiliation(s):  Laboratory of Fruit Quality Biology / the State Agriculture Ministry Laboratory of Horticultural Plant Growth, Development and Quality Improvement, Fruit Science Institute, College of Agriculture and Biotechnology, Zhejiang University, Hangzhou 310058, China; more

Corresponding email(s):   caoji88@zju.edu.cn, jiangli49@zju.edu.cn

Key Words:  Disulfiram (DSF), Cisplatin (DDP), DNA damage, Fanconi anemia (FA) repair, Chemotherapy


Meng YUAN, Qian WU, Mingyang ZHANG, Minshan LAI, Wenbo CHEN, Jianfeng YANG, Li JIANG, Ji CAO. Disulfiram enhances the antitumor activity of cisplatin by inhibiting the Fanconi anemia repair pathway[J]. Journal of Zhejiang University Science B, 2023, 24(3): 207-220.

@article{title="Disulfiram enhances the antitumor activity of cisplatin by inhibiting the Fanconi anemia repair pathway",
author="Meng YUAN, Qian WU, Mingyang ZHANG, Minshan LAI, Wenbo CHEN, Jianfeng YANG, Li JIANG, Ji CAO",
journal="Journal of Zhejiang University Science B",
volume="24",
number="3",
pages="207-220",
year="2023",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2200405"
}

%0 Journal Article
%T Disulfiram enhances the antitumor activity of cisplatin by inhibiting the Fanconi anemia repair pathway
%A Meng YUAN
%A Qian WU
%A Mingyang ZHANG
%A Minshan LAI
%A Wenbo CHEN
%A Jianfeng YANG
%A Li JIANG
%A Ji CAO
%J Journal of Zhejiang University SCIENCE B
%V 24
%N 3
%P 207-220
%@ 1673-1581
%D 2023
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2200405

TY - JOUR
T1 - Disulfiram enhances the antitumor activity of cisplatin by inhibiting the Fanconi anemia repair pathway
A1 - Meng YUAN
A1 - Qian WU
A1 - Mingyang ZHANG
A1 - Minshan LAI
A1 - Wenbo CHEN
A1 - Jianfeng YANG
A1 - Li JIANG
A1 - Ji CAO
J0 - Journal of Zhejiang University Science B
VL - 24
IS - 3
SP - 207
EP - 220
%@ 1673-1581
Y1 - 2023
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2200405


Abstract: 
A series of chemotherapeutic drugs that induce DNA damage, such as cisplatin (DDP), are standard clinical treatments for ovarian cancer, testicular cancer, and other diseases that lack effective targeted drug therapy. Drug resistance is one of the main factors limiting their application. Sensitizers can overcome the drug resistance of tumor cells, thereby enhancing the antitumor activity of chemotherapeutic drugs. In this study, we aimed to identify marketable drugs that could be potential chemotherapy sensitizers and explore the underlying mechanisms. We found that the alcohol withdrawal drug disulfiram (DSF) could significantly enhance the antitumor activity of DDP. JC-1 staining, propidium iodide (PI) staining, and western blotting confirmed that the combination of DSF and DDP could enhance the apoptosis of tumor cells. Subsequent RNA sequencing combined with Gene Set Enrichment Analysis (GSEA) pathway enrichment analysis and cell biology studies such as immunofluorescence suggested an underlying mechanism: DSF makes cells more vulnerable to DNA damage by inhibiting the fanconi anemia (FA) repair pathway, exerting a sensitizing effect to DNA damaging agents including platinum chemotherapy drugs. Thus, our study illustrated the potential mechanism of action of DSF in enhancing the antitumor effect of DDP. This might provide an effective and safe solution for combating DDP resistance in clinical treatment.

双硫仑通过抑制范可尼贫血修复途径增加顺铂的抗肿瘤活性

袁梦1,吴倩2,张明炀2,赖泯汕2,3,陈文博2,3,杨建锋4,5,蒋莉6,曹戟2,6,7
1浙江大学农业与生物技术学院,果实品质生物实验室 / 农业部园艺作物生长发育与品质调实验室,中国杭州市,310058
2浙江大学药学院,浙江省抗癌药物研究重点实验室药理毒理研究所,中国杭州市,310058
3浙江大学工程师学院,中国杭州市,310015
4浙江大学医学院附属杭州市第一人民医院,消化内科,中国杭州市,310006
5浙江省胆胰疾病中西医结合重点实验室,中国杭州市,310006
6浙江大学智能创新药物研究院,中国杭州市,310018
7浙江大学癌症研究院,中国杭州市,310058
概要:由于缺乏有效的靶向药物,顺铂(DDP)等一系列DNA损伤诱导剂一直是卵巢癌、睾丸癌等恶性肿瘤的重要临床治疗药物。然而,临床上出现的耐药性是限制该类药物应用的主要因素之一。药物增敏剂可以克服肿瘤细胞耐药性,从而增强化疗药物的抗肿瘤活性。在本研究中,我们旨在从上市药物中发现潜在的化疗药物增敏剂,并探索其潜在的作用机制。通过系统筛选,我们发现戒酒药物双硫仑(DSF)可以增强DDP的抗肿瘤活性。通过JC-1染色、碘化丙啶(PI)染色和蛋白质印迹等实验证实DSF和DDP的合用可协同促进肿瘤细胞发生凋亡。通过RNA测序结合基因富集分析(GSEA)以及免疫荧光等细胞生物学实验,我们发现DSF协同DDP抗肿瘤作用的潜在分子机制:DSF通过抑制范可尼贫血(FA)修复途径使肿瘤细胞更容易发生DNA损伤,因此可对包括铂类化疗药物在内的引起DNA损伤的药物产生增敏作用。我们的这项研究揭示了DSF在增强DDP抗肿瘤作用方面的潜在机制,为临床治疗中的DDP耐药提供了一种潜在的安全有效的解决方案。

关键词:双硫仑;顺铂;DNA损伤;范可尼贫血(FA)修复;化疗

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]BaiZS, PengYL, YeXY, et al., 2022. Autophagy and cancer treatment: four functional forms of autophagy and their therapeutic applications. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(2):89-101.

[2]BrabecV, NovákováO, 2006. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat, 9(3):111-122.

[3]CastellaM, JacquemontC, ThompsonEL, et al., 2015. FANCI regulates recruitment of the FA core complex at sites of DNA damage independently of FANCD2. PLoS Genet, 11(10):e1005563.

[4]ChenSY, ChangYL, LiuST, et al., 2021. Differential cytotoxicity mechanisms of copper complexed with disulfiram in oral cancer cells. Int J Mol Sci, 22(7):3711.

[5]ChenZ, ChenJJ, 2021. Mass spectrometry-based protein‒protein interaction techniques and their applications in studies of DNA damage repair. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(1):1-20.

[6]FangL, QiH, WangP, et al., 2022. UPF1 increases amino acid levels and promotes cell proliferation in lung adenocarcinoma via the eIF2α-ATF4 axis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):863-875.

[7]FengYL, LiuSC, ChenRD, et al., 2021. Target binding and residence: a new determinant of DNA double-strand break repair pathway choice in CRISPR/Cas9 genome editing. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(1):73-86.

[8]GalluzziL, SenovillaL, VitaleI, et al., 2012. Molecular mechanisms of cisplatin resistance. Oncogene, 31(15):1869-1883.

[9]GuoLM, CuiJ, WangHR, et al., 2021. Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways. Mol Ther Oncolytics, 20:119-131.

[10]HalatschME, KastRE, Karpel-MasslerG, et al., 2021. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neuro-Oncol Adv, 3(1):vdab075.

[11]IshiaiM, 2021. Regulation of the fanconi anemia DNA repair pathway by phosphorylation and monoubiquitination. Genes, 12(11):1763.

[12]JangraA, ChoiSA, YangJ, et al., 2020. Disulfiram potentiates the anticancer effect of cisplatin in atypical teratoid/rhabdoid tumors (AT/RT). Cancer Lett, 486:38-45.

[13]KimSK, KimH, LeeDH, et al., 2013. Reversing the intract

[14]able nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS ONE, 8(10):e78130.

[15]KitaY, HamadaA, SaitoR, et al., 2019. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. Br J Cancer, 121(12):‍1027-1038.

[16]LeeJO, KangMJ, ByunWS, et al., 2019. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51. Breast Cancer Res, 21:115.

[17]LiangZR, ZhangT, ZhanT, et al., 2021. Metformin alleviates cisplatin-induced ototoxicity by autophagy induction possibly via the AMPK/FOXO3a pathway. J Neurophysiol, 125(4):1202-1212.

[18]LiuCC, WuCL, LinMX, et al., 2021. Disulfiram sensitizes a therapeutic-resistant glioblastoma to the TGF-β receptor inhibitor. Int J Mol Sci, 22(19):10496.

[19]MajeraD, SkrottZ, ChromaK, et al., 2020. Targeting the NPL4 adaptor of p97/VCP segregase by disulfiram as an emerging cancer vulnerability evokes replication stress and DNA damage while silencing the ATR pathway. Cells, 9(2):469.

[20]MakovecT, 2019. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol, 53(2):148-158.

[21]MinKA, YuFQ, YangVC, et al., 2010. Transcellular transport of heparin-coated magnetic iron oxide nanoparticles (Hep-MION) under the influence of an applied magnetic field. Pharmaceutics, 2(2):119-135.

[22]NakanoT, WarnerKA, OklejasAE, et al., 2021. mTOR inhib

[23]ition ablates cisplatin-resistant salivary gland cancer stem cells. J Dent Res, 100(4):377-386.

[24]NechushtanH, HamamrehY, NidalS, et al., 2015. A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist, 20(4):366-367.

[25]ParkYM, GoYY, ShinSH, et al., 2018. Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death. PLoS ONE, 13(9):e0203069.

[26]QiX, YanDH, ZuoJC, et al., 2021. Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(12):1053-1059.

[27]RenXY, LiYC, ZhouY, et al., 2021. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol, 46:102122.

[28]RochaCRR, SilvaMM, QuinetA, et al., 2018. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics, 73(S1):e478s.

[29]SchmidtovaS, KalavskaK, GercakovaK, et al., 2019. Disulfiram overcomes cisplatin resistance in human embryonal carcinoma cells. Cancers, 11(9):1224.

[30]SkrottZ, MistrikM, AndersenKK, et al., 2017. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature, 552(7684):194-199.

[31]SkrottZ, MajeraD, GurskyJ, et al., 2019. Disulfiram’s anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase. Oncogene, 38(40):6711-6722.

[32]SmogorzewskaA, MatsuokaS, VinciguerraP, et al., 2007. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell, 129(2):289-301.

[33]WangK, MichelakosT, WangB, et al., 2021. Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation. Cancer Lett, 505:37-48.

[34]WuQ, ZhangMY, WenYM, et al., 2022. Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics. Eur J Pharmacol, 926:175035.

[35]XiaL, LinHX, ZhouYM, et al., 2022. ZNF750 facilitates carcinogenesis via promoting the expression of long non-coding RNA CYTOR and influences pharmacotherapy response in colon adenocarcinoma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(7):587-596.

[36]XuYQ, ZhouQ, FengXL, et al., 2020. Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways. Biomed Pharmacother, 126:110048.

[37]YangYY, Lindsey-BoltzLA, VaughnCM, et al., 2021. Circadian clock, carcinogenesis, chronochemotherapy connections. J Biol Chem, 297(3):101068.

[38]YangZ, GuoF, AlbersAE, et al., 2019. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. Biomed Pharmacother, 113:108727.

[39]YardeDN, OliveiraV, MathewsL, et al., 2009. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res, 69(24):9367-9375.

[40]ZhangHJ, ChenD, RinglerJ, et al., 2010. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res, 70(10):3996-4004.

[41]ZhaoLJ, TengB, WenLJ, et al., 2014. mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma. Int J Clin Exp Med, 7(2):337-347.

[42]ZhongWW, WangDJ, YaoB, et al., 2021. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(8):664-681.

[43]ZirjacksL, StranskyN, KlumppL, et al., 2021. Repurposing disulfiram for targeting of glioblastoma stem cells: an in vitro study. Biomolecules, 11(11):1561.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE